Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Crohn's disease is an inflammatory disorder that can affect any part of the gastrointestinal
(GI) tract. Some patients still experience persistent diarrhea or other symptoms such as
abdominal pain even when their Crohn's disease is in remission. Diarrhea and/or abdominal
pain that is not responsive to standard therapies can significantly affect a patient's
quality of life and ability to work. The purpose of this study is to test the safety and
effectiveness of the drug ranolazine in reducing Crohn's disease-associated diarrhea and
other symptoms. Ranolazine is approved by the US Food & Drug Administration (FDA) for chronic
angina (a heart condition). This study is investigating if ranolazine could be used in the
setting of Crohn's disease.